Research programme: histone and peptide based therapeutics - SymbioTec

Drug Profile

Research programme: histone and peptide based therapeutics - SymbioTec

Alternative Names: rhH1 x; rhH1.x

Latest Information Update: 25 Jan 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SymbioTec
  • Class Peptides; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jan 2012 SymbioTec has been acquired by Xenetic Biosciences
  • 09 Jul 2010 No development reported - Preclinical for Cancer in Germany (unspecified route)
  • 24 Apr 2007 Preclinical trials in Acute myeloid leukaemia in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top